Organisms | Evidence |
---|---|
Mus musculus (house mouse) | |
Rattus norvegicus (Norway rat) | |
Homo sapiens (human) | |
Drosophila melanogaster (fruit fly) | |
Streptococcus pneumoniae |
Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Product | Reducing terminal(Product) | Reference |
---|---|---|---|---|---|---|
B4GALT5 | (not applicable) |
|
[beta]-S-pNP |
|
[beta]-S-pNP | |
B3GALT2 | UDP-Gal |
|
Lemieux |
|
Lemieux | |
B4GALT2 | UDP-Gal |
|
Benzyl-[beta] |
|
Benzyl-[beta] | |
B4GALT1 | UDP-Gal |
|
R |
|
R | |
B3GALT5 | UDP-Gal |
|
R |
|
R |
Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Product | Reducing terminal(Product) | Reference |
---|---|---|---|---|---|---|
B4GALT1 | UDP-Gal |
|
|
|||
B4GALT4 | UDP-Gal |
|
|
|||
B4GALT3 | UDP-Gal |
|
4-Me-lumbelyl-[beta] |
|
4-Me-lumbelyl-[beta] | |
B4GALT2 | UDP-Gal |
|
[beta]-S-pNP |
|
[beta]-S-pNP | |
B4GALT3 | UDP-Gal |
|
p-Nitrophenyl-1-thio-[beta] |
|
p-Nitrophenyl-1-thio-[beta] |
Pathway Name | Organism |
---|---|
Antimicrobial peptides | Drosophila melanogaster |
Antimicrobial peptides | Rattus norvegicus |
Antimicrobial peptides | Danio rerio |
Antimicrobial peptides | Xenopus tropicalis |
Antimicrobial peptides | Gallus gallus |
Antimicrobial peptides | Homo sapiens |
Antimicrobial peptides | Canis familiaris |
Antimicrobial peptides | Dictyostelium discoideum |
Antimicrobial peptides | Bos taurus |
Antimicrobial peptides | Mus musculus |
RES 1b:b-dglc-HEX-1:5 2s:n-acetyl LIN 1:1d(2+1)2n
PubMed ID | Title | First Author | Publication Date | Source |
---|---|---|---|---|
38773089 | Human CD4-binding site antibody elicited by polyvalent DNA prime-protein boost vaccine neutralizes cross-clade tier-2-HIV strains | Wang S | 2024 May 21 |
|
38773637 | O-GlcNAcylation: roles and potential therapeutic target for bone pathophysiology | Yan X | 2024 May 21 |
|
38769387 | Structure and mechanism of lysosome transmembrane acetylation by HGSNAT | Xu R | 2024 May 20 |
|
38753503 | Ultrapotent influenza hemagglutinin fusion inhibitors developed through SuFEx-enabled high-throughput medicinal chemistry | Kitamura S | 2024 May 16 |
|
38742627 | Structural basis for double-stranded RNA recognition by SID1 | Wang R | 2024 May 14 |
|
38670113 | Eliciting a single amino acid change by vaccination generates antibody protection against group 1 and group 2 influenza A viruses | Ray R | 2024 May 14 |
|
38624232 | Epitopes of an antibody that neutralizes a wide range of SARS-CoV-2 variants in a conserved subdomain 1 of the spike protein | Ishimaru H | 2024 May 14 |
|
38745047 | Synthesis and anti-inflammatory activities of two new N-acetyl glucosamine derivatives | Zhang Z | 2024 May 14 |
|
39046448 | Author response: Glycan-shielded homodimer structure and dynamical features of the canine distemper virus hemagglutinin relevant for viral entry and efficient vaccination | Fukuhara H | 2024 May 13 |
|
38740785 | Enhanced potency of an IgM-like nanobody targeting conserved epitope in SARS-CoV-2 spike N-terminal domain | Liu B | 2024 May 13 |
|
Title | Authors | Source | Publication Date | PubMed ID |
---|---|---|---|---|
Dynamic glycosylation of the transcription factor CREB: a potential role in gene regulation. |
|
J Am Chem Soc | 2003 Jun 4 | 12769553 |
Effect of okadaic acid on O-linked N-acetylglucosamine levels in a neuroblastoma cell line. |
|
Biochim Biophys Acta | 1999 Oct 18 | 10572927 |
Regulation of a cytosolic and nuclear O-GlcNAc transferase. Role of the tetratricopeptide repeats. |
|
J Biol Chem | 1999 Nov 5 | 10542233 |
An N-terminal region of Sp1 targets its proteasome-dependent degradation in vitro. |
|
J Biol Chem | 1999 May 21 | 10329728 |
Vertebrate lens alpha-crystallins are modified by O-linked N-acetylglucosamine. |
|
J Biol Chem | 1992 Jan 5 | 1730617 |
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
This work is licensed under Creative Commons Attribution 4.0 International
GlyCosmos Portal v4.2.1
Last updated: April 7, 2025